A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


November 15, 2012

Hep C Protease Inhibitor Incivek Is Safe, Effective for HIV Coinfection

People living with both HIV and the hepatitis C virus (HCV) experience high hepatitis cure rates from an Incivek (telaprevir)–based triple combination therapy, compared with those taking interferon and ribavirin alone, aidsmap reports. Vertex Pharmaceuticals presented the results of its Phase II trial at the annual meeting of the American Association for the Study of Liver Diseases (AALSD) in Boston. The findings echoed and re-affirmed previous results announced at the 2012 Conference on Retroviruses and Opportunistic Infections in March.

The randomized controlled trial examined the effects of Incivek along with pegylated interferon and ribavirin among HCV treatment-naive coinfected people with HCV genotype-1, the most common strain and the most difficult to treat. Divided into two arms, the study examined 13 participants with CD4 counts above 500 who had not yet taken antiretrovirals (ARVs) for HIV, as well as 47 patients on ARVs with a stable viral load. All participants randomly received either Incivek or a placebo along with pegylated interferon and ribavirin for 12 weeks, followed by another 36 weeks of just the peg-interferon plus ribavirin combination.

Across the board, 74 percent of those taking Incivek triple combination therapy maintained a sustained virological response (SVR, considered a cure) 24 weeks after finishing treatment, while only 45 percent of the control group achieved the same. Those not taking antiretrovirals experienced respective SVR rates of 71 and 33 percent. Side effects were elevated among those taking Incivek, with the most notable increased including itching, headache, nausea, skin rash and dizziness. However, the overall safety and tolerability profile of the triple combination therapy proved comparable to previous studies of people living with only hepatitis C.

To read the aidsmap article, click here.

Search: Hepatitis C, HCV, virus, HIV, cure, Incivek, telaprevir, triple combination therapy, Vertex Pharmaceuticals, American Association for the Study of Liver Diseases, AASLD, Conference on Retroviruses and Opportunistic Infections, CROI, pegylated interferon, ribavirin, treatment-naive, sustained virologic response, SVR, safety, tolerability

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (2 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.